SEC Filing Summary: Healthcare Acquisition Corp. (HAQ) Form 8-K
Business Context and Reporting Period
Date of Report: January 19, 2007
Registrant: Healthcare Acquisition Corp. (HAQ), a Delaware corporation and Special Purpose Acquisition Company (SPAC).
Target Company: PharmAthene, Inc., a biopharmaceutical company focused on biodefense therapeutics.
Event: Entry into a definitive Merger Agreement. HAQ's wholly-owned subsidiary, PAI Acquisition Corp., will merge with PharmAthene, making PharmAthene a wholly-owned subsidiary of HAQ. Upon consummation, HAQ will change its name to PharmAthene, Inc.
Key Financial Metrics and Transaction Terms
Merger Consideration: PharmAthene stockholders and noteholders will receive:
- Equity: 12,500,000 shares of HAQ common stock.
- Debt: $12,500,000 in 8% convertible notes of HAQ (in exchange for $11,800,000 of outstanding PharmAthene notes).
- Milestone Payments: Up to $10,000,000 contingent on meeting specific conditions.
Capital Structure Adjustments:
- HAQ will assume outstanding vested and unvested options and warrants of PharmAthene on economically equivalent terms.
- A new incentive plan will be established, reserving an additional 3,000,000 shares of HAQ common stock.
- Lock-up provisions apply: 50% of shares released after six months; remaining 50% after 12 months.
Financial Data Availability: The filing states that PharmAthene's financial information is unaudited, prepared as a private company, and does not conform to SEC Regulation S-X. Specific revenue, profit, cash flow, or margin figures for PharmAthene are not provided in this text.
Material Changes and Governance
Change in Control: The merger will result in a change of control for HAQ. PharmAthene securityholders will receive significant board representation rights tied to the outstanding 8% convertible notes.
- While at least 30% of the 8% convertible notes remain outstanding, the board size is capped at seven directors.
- Noteholders have the right to elect three members to the board of directors.
- Noteholders may appoint two of the three members of the corporate governance/nominating and compensation committees.
Timeline Extension: HAQ's deadline to complete a business combination has been extended to August 3, 2007.
Outlook, Risks, and Management Commentary
Business Strategy: PharmAthene focuses on biodefense products, specifically:
- Valortim: A monoclonal antibody for anthrax prevention and treatment (co-developed with Medarex). It has received FDA Fast Track and Orphan Drug status. Phase I trials showed no serious adverse events.
- Protexia: A bioscavenger for nerve agent poisoning. In September 2006, PharmAthene was awarded a DoD contract with a potential value of $213 million for advanced development and initial procurement.
Risks and Contingencies:
- Regulatory Approval: Success depends on FDA approval and government procurement contracts. Biodefense drugs have expedited pathways but still require safety and efficacy data.
- Government Funding: Revenue is heavily dependent on U.S. government contracts (DoD, Project BioShield).
- Merger Conditions: Closing is subject to HAQ stockholder approval, SEC approval of the proxy statement, and the absence of material adverse changes.
- Termination Fees: A $250,000 termination fee is payable by either party under specific breach or failure-to-close scenarios.
Investor Verification Checklist
- Verify the final terms of the Merger Agreement and the definitive proxy statement once filed with the SEC.
- Confirm the status of the $213 million DoD contract for Protexia and the specific milestones required for funding release.
- Review the unaudited financial statements of PharmAthene to be included in the proxy statement for a clear picture of liquidity and burn rate.
- Monitor the timeline for the filing of the preliminary proxy statement (targeted by February 14, 2007) and the special stockholder meeting.
- Assess the competitive landscape for anthrax therapeutics and nerve agent antidotes as detailed in the filing.